Plasma p-tau217-Triggered Exosome Dosing Maximizes lncRNA-0021 Therapeutic Window

🧫 Experiment Protocol In-VivoAlzheimer disease3xTg-AD mice with stratified p-tau217 status, IV exosome dosingproposed

Determine the optimal dosing window for p-tau217-triggered hUC-MSC exosome administration delivering lncRNA-0021, based on biomarker stratification, and evaluate neuroprotective efficacy in 3xTg-AD mice.

PRIMARY OUTCOME

Plasma p-tau217 biomarker levels and amyloid/tau pathology burden

EXPECTED OUTCOMES

P-tau217-stratified dosing reduces amyloid and tau pathology by >30% and improves cognitive performance (Y-maze, Barnes maze) vs. standard-dose exosome or vehicle controls.

SUCCESS CRITERIA

p-Tau217 plasma levels (ULSA), amyloid/tau IHC burden, cognitive behavioral scores; threshold: p < 0.05 vs. vehicle.

PROTOCOL

in-vivo

Source: auto-generated